• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Ivosidenib and azacitidine showed significant clinical benefit in newly diagnosed IDH1-mutated acute myeloid leukemia

byJohan PushaniandSze Wah Samuel Chan
May 2, 2022
in Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Event-free survival and median overall survival were significantly longer in the combination group

2. Febrile neutropenia and infections occurred less frequently in the combination group, while neutropenia and bleeding had a higher occurrence

Evidence Rating Level: 1 (Excellent)

Study Rundown: Certain patients, especially of older age, with acute myeloid leukemia are considered unfit to receive induction chemotherapy and are more limited in their treatment options. This study explored the use of (an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1)) and azacitidine (a DNA methyltransferase inhibitor) on newly diagnosed IDH1-mutated acute myeloid leukemia patients who were ineligible for induction chemotherapy. Patients were assigned to receive either ivosidenib and azacitidine or placebo and azacitidine. Event free survival (EFS) and median overall survival (OS) were significantly longer in the combination group. A higher proportion of patients in the combination group had a complete remission and transfusion independence. Health-related quality of life scores were higher in the combination group. When indirectly compared to venetoclax plus azacitidine, the ivosidenib and azacitidine had a longer EFS and higher proportion of patients with complete remission, though there is caution in cross-trial comparisons. Adverse events that occurred were expected of acute leukemia treatments. Adverse events grade 3 or higher occurred in nearly all patients and were comparable across both groups. Febrile neutropenia and infections occurred less frequently in the combination group, while neutropenia and bleeding occurred more frequently. Limitations to this study include its small sample size and its indirect comparison to other first-line therapies. The strength of this study is that it provides a treatment option to IDH1-mutated acute myeloid leukemia patients ineligible for induction chemotherapy. Overall, this study showed the clinical benefits of ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia and is a viable treatment option.

Click to read the study in NEJM

Relevant Reading: Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm

In-Depth [randomized control trial]: This global, phase III trial randomly assigned 146 patients with newly diagnosed IDH1-mutated acute myeloid leukemia patients who were ineligible for induction chemotherapy; 72 in the ivosidenib and azacitidine group and 74 in the placebo and azacitidine. EFS was significantly longer in the combination group (hazard ratio [HR] for treatment failure, relapse from remission, or death, 0.33; 95% confidence interval [CI], 0.16 to 0.69; P=0.002). Median OS was 24.0 months for the combination group and 7.9 months for the placebo group (HR for death, 0.44; 95% CI, 0.27 to 0.73; P=0.001). Complete remission occurred in 47% of patients in the combination group (95% CI, 35 to 59) and in 15% of patients in the placebo group (95% CI, 8 to 25). Transfusion independence was reached in 46% of patients in the combination group, compared to 18% in the placebo group (P=0.006). When indirectly compared to venetoclax plus azacitidine, ivosidenib plus azacitidine had a 6.5 month increase in median OS and 18.9% increase in complete remissions. Adverse events of grades 3 or higher occurred in 93% of patients in the combination group and 95% in the placebo group. Main differences in occurrence of adverse events of any grade were observed with febrile neutropenia (combination group 28%, placebo group 34%), infections (28% and 49%), neutropenia (28% and 16%), bleeding (41% and 29%), and differentiation syndrome (14% and 8%). Overall, ivosidenib and azacitidine therapy increased EFS, median OS, quality of life, transfusion independence, and incidence of complete remission compared to placebo and azacitidine.

RELATED REPORTS

Ivosidenib and azacitidine provide significant benefits in IDH1-mutated acute myeloid leukemia

#VisualAbstract Intensive chemotherapy is associated with better long-term survival in older patients with acute myeloid leukemia

Ivosidenib improves overall survival in IDH1-mutant advanced cholangiocarcinoma as compared to placebo

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: acute myeloid leukemia (AML)IDH-1ivosidenib
Previous Post

Lenvatinib plus pembrolizumab show similar health-related quality-of-life outcomes in patients with advanced renal cell carcinoma compared to sunitinib

Next Post

Symptoms of posttraumatic stress disorder highly prevalent among family members of patients admitted to the intensive care unit with COVID-19

RelatedReports

Delaying intrathecal therapy in leukemia may preclude need for cranial radiotherapy
Chronic Disease

Ivosidenib and azacitidine provide significant benefits in IDH1-mutated acute myeloid leukemia

May 13, 2022
#VisualAbstract Intensive chemotherapy is associated with better long-term survival in older patients with acute myeloid leukemia
StudyGraphics

#VisualAbstract Intensive chemotherapy is associated with better long-term survival in older patients with acute myeloid leukemia

November 27, 2021
Patient Basics: Gallbladder and Bile Duct Cancer
Gastroenterology

Ivosidenib improves overall survival in IDH1-mutant advanced cholangiocarcinoma as compared to placebo

October 4, 2021
#VisualAbstract Adding uproleselan to chemotherapy in patients with relapsed or refractory acute myeloid leukemia was well-tolerated with high remission rates
StudyGraphics

#VisualAbstract Adding uproleselan to chemotherapy in patients with relapsed or refractory acute myeloid leukemia was well-tolerated with high remission rates

September 30, 2021
Next Post

Symptoms of posttraumatic stress disorder highly prevalent among family members of patients admitted to the intensive care unit with COVID-19

Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors

Increases in muscle-strengthening activities may reduce mortality risk and certain diseases

#VisualAbstract: Aromatase inhibitors significantly reduce recurrence in  premenopausal women with ER+ breast cancer and ovarian suppression

#VisualAbstract: Aromatase inhibitors significantly reduce recurrence in premenopausal women with ER+ breast cancer and ovarian suppression

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Mycobacterium abscessus infections after cardiac surgery linked to hospital water system
  • The 2 Minute Medicine Podcast Episode 11
  • Wellness Check: Spirituality
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options